{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T02:01:29Z","timestamp":1768528889092,"version":"3.49.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-75208-4","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T07:06:06Z","timestamp":1730703966000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7118-7958","authenticated-orcid":false,"given":"Metin","family":"Eser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5027-6756","authenticated-orcid":false,"given":"Gulam","family":"Hekimoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8481-9803","authenticated-orcid":false,"given":"Murat Hakki","family":"Yarar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9516-0047","authenticated-orcid":false,"given":"Sezin","family":"Canbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0406-715X","authenticated-orcid":false,"given":"Melike","family":"Ozcelik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"75208_CR1","doi-asserted-by":"publisher","first-page":"CRA7506","DOI":"10.1200\/jco.2011.29.18_suppl.cra7506","volume":"29","author":"MG Kris","year":"2011","unstructured":"Kris, M. G. et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI\u2019s Lung Cancer Mutation Consortium (LCMC). J. Clin. Oncol. 29, CRA7506\u2013CRA7506 (2011).","journal-title":"J. Clin. Oncol."},{"key":"75208_CR2","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature11404","volume":"489","author":"The Cancer Genome Atlas Research Network","year":"2012","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519\u2013525 (2012).","journal-title":"Nature"},{"key":"75208_CR3","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1200\/JCO.2012.48.1390","volume":"31","author":"FA Shepherd","year":"2013","unstructured":"Shepherd, F. A. et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non\u2013non-small-cell lung cancer in four trials of adjuvant chemotherapy. J. Clin. Oncol. 31, 2173\u20132181 (2013).","journal-title":"J. Clin. Oncol."},{"key":"75208_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0789-x","volume":"17","author":"M Rom\u00e1n","year":"2018","unstructured":"Rom\u00e1n, M. et al. KRAS oncogene in non-small cell lung cancer: Clinical perspectives on the treatment of an old target. Mol. Cancer 17, 1\u201314 (2018).","journal-title":"Mol. Cancer"},{"key":"75208_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.lungcan.2009.09.010","volume":"69","author":"A Kalikaki","year":"2010","unstructured":"Kalikaki, A. et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 69, 110\u2013115 (2010).","journal-title":"Lung Cancer"},{"key":"75208_CR6","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","volume":"8","author":"F Skoulidis","year":"2018","unstructured":"Skoulidis, F. et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 8, 822\u2013835 (2018).","journal-title":"Cancer Discov."},{"key":"75208_CR7","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","volume":"5","author":"F Skoulidis","year":"2015","unstructured":"Skoulidis, F. et al. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov. 5, 860\u2013877 (2015).","journal-title":"Cancer Discov."},{"key":"75208_CR8","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","volume":"24","author":"KC Arbour","year":"2018","unstructured":"Arbour, K. C. et al. Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer. Clin. Cancer Res. 24, 334\u2013340 (2018).","journal-title":"Clin. Cancer Res."},{"key":"75208_CR9","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jtho.2018.12.013","volume":"14","author":"M Scheffler","year":"2019","unstructured":"Scheffler, M. et al. K-ras mutation subtypes in NSCLC and associated co-occurring mutations in other oncogenic pathways. J. Thorac. Oncol. 14, 606\u2013616 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"75208_CR10","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon, J. et al. The clinical KRAS (G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575, 217\u2013223 (2019).","journal-title":"Nature"},{"key":"75208_CR11","doi-asserted-by":"publisher","first-page":"33922","DOI":"10.18632\/oncotarget.15412","volume":"8","author":"G Fan","year":"2017","unstructured":"Fan, G. et al. Prognostic value of EGFR and KRAS in circulating tumor DNA in patients with advanced non-small cell lung cancer: A systematic review and meta-analysis. Oncotarget 8, 33922 (2017).","journal-title":"Oncotarget"},{"key":"75208_CR12","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00428-020-02756-1","volume":"477","author":"EA Karatrasoglou","year":"2020","unstructured":"Karatrasoglou, E. A. et al. Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: Correlation with clinical data. Virchows Arch. 477, 207\u2013217 (2020).","journal-title":"Virchows Arch."},{"key":"75208_CR13","doi-asserted-by":"publisher","first-page":"4208","DOI":"10.1200\/JCO.20.00744","volume":"38","author":"TF Burns","year":"2020","unstructured":"Burns, T. F., Borghaei, H., Ramalingam, S. S., Mok, T. S. & Peters, S. Targeting KRAS-mutant non-small-cell lung cancer: One mutation at a time, with a focus on KRAS G12C mutations. J. Clin. Oncol. 38, 4208 (2020).","journal-title":"J. Clin. Oncol."},{"key":"75208_CR14","doi-asserted-by":"publisher","first-page":"xi63","DOI":"10.1093\/annonc\/mdz453.001","volume":"30","author":"RS Herbst","year":"2019","unstructured":"Herbst, R. S. et al. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042. Ann. Oncol. 30, xi63\u2013xi64 (2019).","journal-title":"Ann. Oncol."},{"key":"75208_CR15","doi-asserted-by":"publisher","first-page":"xi64","DOI":"10.1093\/annonc\/mdz453.002","volume":"30","author":"S Gadgeel","year":"2019","unstructured":"Gadgeel, S. et al. KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC. Ann. Oncol. 30, xi64\u2013xi65 (2019).","journal-title":"Ann. Oncol."},{"key":"75208_CR16","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","volume":"384","author":"EB Garon","year":"2014","unstructured":"Garon, E. B. et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): A multicentre, double-blind, randomised phase 3 trial. Lancet 384, 665\u2013673 (2014).","journal-title":"Lancet"},{"key":"75208_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li, M. M. et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: A joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. J. Mol. Diagn. 19, 4\u201323 (2017).","journal-title":"J. Mol. Diagn."},{"key":"75208_CR18","doi-asserted-by":"publisher","first-page":"5731","DOI":"10.1158\/1078-0432.CCR-08-0646","volume":"14","author":"GJ Riely","year":"2008","unstructured":"Riely, G. J. et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin. Cancer Res. 14, 5731\u20135734 (2008).","journal-title":"Clin. Cancer Res."},{"key":"75208_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s13402-012-0078-4","volume":"35","author":"AJ Smits","year":"2012","unstructured":"Smits, A. J. et al. EGFR and KRAS mutations in lung carcinomas in the Dutch population: Increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma. Cell. Oncol. 35, 189\u2013196 (2012).","journal-title":"Cell. Oncol."},{"key":"75208_CR20","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1200\/JCO.2011.35.9638","volume":"29","author":"A Marchetti","year":"2011","unstructured":"Marchetti, A. et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J. Clin. Oncol. 29, 3574\u20133579 (2011).","journal-title":"J. Clin. Oncol."},{"key":"75208_CR21","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3892\/ol.2013.1551","volume":"6","author":"K Takamochi","year":"2013","unstructured":"Takamochi, K. et al. Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers. Oncol. Lett. 6, 1207\u20131212 (2013).","journal-title":"Oncol. Lett."},{"key":"75208_CR22","first-page":"25","volume":"9","author":"E Syahruddin","year":"2018","unstructured":"Syahruddin, E. et al. Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients. Lung Cancer: Targets Ther. 9, 25\u201334 (2018).","journal-title":"Lung Cancer: Targets Ther."},{"key":"75208_CR23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell, R. et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 13, 239\u2013246 (2012).","journal-title":"Lancet Oncol."},{"key":"75208_CR24","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","volume":"27","author":"AT Shaw","year":"2009","unstructured":"Shaw, A. T. et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 27, 4247 (2009).","journal-title":"J. Clin. Oncol."},{"key":"75208_CR25","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nature05945","volume":"448","author":"M Soda","year":"2007","unstructured":"Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561\u2013566 (2007).","journal-title":"Nature"},{"key":"75208_CR26","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-08-3248","volume":"15","author":"K Takeuchi","year":"2009","unstructured":"Takeuchi, K. et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 15, 3143\u20133149 (2009).","journal-title":"Clin. Cancer Res."},{"key":"75208_CR27","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard, D. et al. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: An open-label, multicentre phase 2 trial. Lancet Oncol. 17, 984\u2013993 (2016).","journal-title":"Lancet Oncol."},{"key":"75208_CR28","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-13-0657","volume":"19","author":"S Cardarella","year":"2013","unstructured":"Cardarella, S. et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin. Cancer Res. 19, 4532\u20134540 (2013).","journal-title":"Clin. Cancer Res."},{"key":"75208_CR29","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1038\/s41598-022-26776-w","volume":"13","author":"M Xiao","year":"2023","unstructured":"Xiao, M. et al. Comprehensive characterization of B7 family members in NSCLC and identification of its regulatory network. Sci. Rep. 13, 4311 (2023).","journal-title":"Sci. Rep."},{"key":"75208_CR30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.humpath.2018.04.014","volume":"78","author":"LN Toth","year":"2018","unstructured":"Toth, L. N. et al. Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1\/2) mutations. Hum. Pathol. 78, 138\u2013143 (2018).","journal-title":"Hum. Pathol."},{"key":"75208_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S1470-2045(12)70489-8","volume":"14","author":"PA J\u00e4nne","year":"2013","unstructured":"J\u00e4nne, P. A. et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 14, 38\u201347 (2013).","journal-title":"Lancet Oncol."},{"key":"75208_CR32","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","volume":"72","author":"IA Prior","year":"2012","unstructured":"Prior, I. A. et al. A comprehensive survey of Ras mutations in cancer. Cancer Res. 72, 2457\u20132467 (2012).","journal-title":"Cancer Res."},{"key":"75208_CR33","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3346\/jkms.2013.28.10.1555","volume":"28","author":"SS Yoo","year":"2013","unstructured":"Yoo, S. S. et al. RET fusion genes in Korean non-small cell lung cancer. J. Korean Med. Sci. 28, 1555 (2013).","journal-title":"J. Korean Med. Sci."},{"key":"75208_CR34","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.1158\/0008-5472.CAN-07-5084","volume":"68","author":"H Yamamoto","year":"2008","unstructured":"Yamamoto, H. et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res. 68, 6913\u20136921 (2008).","journal-title":"Cancer Res."},{"key":"75208_CR35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00109-016-1382-7","volume":"94","author":"F McCormick","year":"2016","unstructured":"McCormick, F. K-Ras protein as a drug target. J. Mol. Med. 94, 253\u2013258 (2016).","journal-title":"J. Mol. Med."},{"key":"75208_CR36","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2014.58.2007","volume":"33","author":"A Lopez-Chavez","year":"2015","unstructured":"Lopez-Chavez, A. et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: A biomarker-derived, multiarm, multihistology phase II basket trial. J. Clin. Oncol. 33, 1000 (2015).","journal-title":"J. Clin. Oncol."},{"key":"75208_CR37","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1093\/annonc\/mdv072","volume":"26","author":"GR Blumenschein Jr","year":"2015","unstructured":"Blumenschein, G. R. Jr et al. A randomized phase II study of the MEK1\/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Ann. Oncol. 26, 894\u2013901 (2015).","journal-title":"Ann. Oncol."},{"key":"75208_CR38","doi-asserted-by":"crossref","unstructured":"Fakih, M. et al. Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors. 3003\u20133003 (2019).","DOI":"10.1200\/JCO.2019.37.15_suppl.3003"},{"key":"75208_CR39","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. KRASG12C inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383, 1207\u20131217 (2020).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75208-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75208-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75208-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T10:09:01Z","timestamp":1730974141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-75208-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["75208"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-75208-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"27 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The participants have already given informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"This study was approved by the Ethical Committee of Umraniye Training and Research Hospital (Ethics No: B.10.1.TKH.4.34.H.GP.0.01\/271, 10\/08\/2023), School of Medicine, University of Health Sciences, Istanbul, T\u00fcrkiye.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"26581"}}